Keyphrases
Gastroesophageal Junction
75%
Dabigatran
66%
Barrett's Esophagus
66%
Radiofrequency Ablation
66%
Surgery Alone
66%
Dysplasia
57%
Curative Resection
44%
Long-term Survival
44%
Gastroesophageal Junction Cancer
44%
Denmark
43%
Esophageal Cancer
41%
Anastomotic Leakage
41%
Adenocarcinoma
38%
Cardioversion
33%
Osteoporosis
33%
Comorbidity
33%
Cardia Cancer
33%
Adjuvant Chemoradiotherapy
33%
Adjuvant Surgery
33%
Risk Analysis
33%
Thromboembolism
33%
Mural Thrombosis
33%
Peripheral Embolization
33%
Time Trends
33%
Jehovah's Witness Patients
33%
Risk Factor Profile
33%
Preoperative Surgery
33%
Osteoporosis Risk Factors
33%
Comparative Analysis
33%
Post-esophagectomy
33%
Postoperative Complications
33%
Esophagogastric Junction
33%
Teriparatide
33%
Intraocular Pressure Elevation
33%
Outpatient Clinic
33%
Anastomotic Dehiscence
33%
Myocardial Infarction
33%
Main Symptoms
33%
National Database
33%
Neuroendocrine Neoplasms
33%
Cataract Surgery
33%
Prophylactic Treatment
33%
Neuroendocrine Markers
33%
Atypical Femur Fracture
33%
Single Center
33%
Roflumilast
33%
Preoperative Chemotherapy
33%
Gastrointestinal Bleeding
33%
Nonglaucomatous
33%
High-volume Center
33%
Medicine and Dentistry
Malignant Neoplasm
100%
Dysplasia
66%
Radiofrequency Ablation
66%
Barrett Esophagus
66%
Gastroesophageal Junction
50%
Esophagus
46%
Anastomosis Leakage
40%
Cardia
33%
Silent Myocardial Infarction
33%
Embolization
33%
Preoperative Chemotherapy
33%
Esophagectomy
33%
Symptom
33%
Postoperative Complication
33%
Cancer Surgery
33%
Neuroendocrine Tumor
33%
Long Term Survival
33%
Surgery
33%
Neoplasm
27%
Thrombosis
22%
Carcinoma
18%
Neoadjuvant Therapy
13%
Artery Occlusion
11%
Epileptic Absence
11%
Left Ventricle
11%
Leg
11%
Thromboembolism
11%
Echocardiography
11%
Coronary Angiography
11%
Artery
11%
Pathologist
11%
Esophageal Cancer
8%
Adverse Event
8%
Recurrent Disease
8%
Precursor
8%
Alcohol Consumption
6%
Multivariate Analysis
6%
Neoadjuvant Chemotherapy
6%
Survival Rate
6%
Prevalence
6%
Radiation Therapy
6%
Intestinal Metaplasia
5%
Neuroendocrine Differentiation
5%
Synaptophysin
5%
Adenocarcinoma
5%
Haematoxylin
5%
Eosin
5%
Chromogranin A
5%
Pharmacology, Toxicology and Pharmaceutical Science
Dabigatran
66%
Dysplasia
66%
Barrett Esophagus
66%
Gastrointestinal Hemorrhage
33%
Comorbidity
33%
Chemoradiation Therapy
33%
Parathyroid hormone[1-34]
33%
Thromboembolism
33%
Adenocarcinoma
33%
Osteogenesis Imperfecta
33%
Femur Fracture
33%
Cataract
33%
Bleeding
25%
Brinzolamide Plus Timolol
22%
Timolol
22%
Chronic Lung Disease
13%
Loop Diuretic Agent
13%
Overall Survival
11%
Long Term Survival
11%
Fracture Healing
11%
Stomach Adenocarcinoma
11%
Disease Free Survival
11%
Timolol Plus Travoprost
11%
Brimonidine Plus Brinzolamide
11%
Brimonidine Plus Timolol
11%
Latanoprost Plus Timolol
11%
Dorzolamide Plus Timolol
11%
Randomized Controlled Trial
11%
Antivitamin K
8%
Esophagus Cancer
8%
Adverse Event
8%
Recurrent Disease
8%
Hyperthyroidism
6%
Secondary Osteoporosis
6%
Fragility Fracture
6%
Prevalence
6%
Thiazide Diuretic Agent
6%
Estrogen Deficiency
6%
Rheumatoid Arthritis
6%
Glucocorticoid
6%
Intestine Metaplasia
5%
Fracture Nonunion
5%
Bisphosphonic Acid Derivative
5%
Replacement Therapy
5%
